Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 19/20 | 0.73 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6433927 | 0.99 | PGR (0.72) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL91102 | 0.84 | PGR (1.00) | PGR | |
| SCHEMBL5508205 | 0.83 | PGR (1.00) | PGR | |
| SCHEMBL5499653 | 0.81 | PGR (0.95) | PGR | |
| SCHEMBL3521215 | 0.81 | PGR (0.56) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5505137 | 0.78 | PGR (0.91) | PGR | |
| SCHEMBL7686696 | 0.77 | PGR (0.74) | PGR | |
| SCHEMBL1223262 | 0.76 | PGR (0.55) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1222740 | 0.75 | PGR (0.55) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3523720 | 0.75 | PGR (1.00) | PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1173433-B1 | CYANOPYRROLES AS PROGESTERONE RECEPTOR AGONISTS | WYETH CORP (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050171186-A1 | 3-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)benzonitrile; 5'-(5-Cyano-1-methyl-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide; progesterone receptor agonist; mixture with estrone (estrogen); hormone replacement therapy, contraception; anticarcinogenic | WYETH (US) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171186-A1 | 3-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)benzonitrile; 5'-(5-Cyano-1-methyl-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide; progesterone receptor agonist; mixture with estrone (estrogen); hormone replacement therapy, contraception; anticarcinogenic | PGR, ESR1, PGRMC1 | PGR 1/4885PDE4A 4019/4885PDE4B 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.